Search

Your search keyword '"Oravec, Caitlin P"' showing total 10 results
Start Over Author "Oravec, Caitlin P"
10 results on '"Oravec, Caitlin P"'

4. Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research

Author

O’Horo, John Charles, primary, Cerhan, James R., additional, Cahn, Elliot J., additional, Bauer, Philippe R., additional, Temesgen, Zelalem, additional, Ebbert, Jon, additional, Abril, Andy, additional, Abu Saleh, Omar M., additional, Assi, Mariam, additional, Berbari, Elie F., additional, Bierle, Dennis M., additional, Bosch, Wendelyn, additional, Burger, Charles D., additional, Cano Cevallos, Edison J., additional, Clements, Casey M., additional, Carmona Porquera, Eva M., additional, Castillo Almeida, Natalia E., additional, Challener, Douglas W., additional, Chesdachai, Supavit, additional, Comba, Isin Y., additional, Corsini Campioli, Cristina G., additional, Crane, Sarah J., additional, Dababneh, Ala S., additional, Enzler, Mark J., additional, Fadel, Hind J., additional, Ganesh, Ravindra, additional, De Moraes, Alice Gallo, additional, Go, John R., additional, Gordon, Joel E., additional, Gurram, Pooja R., additional, Guru, Pramod K., additional, Halverson, Erika L., additional, Harrison, Michael F., additional, Heaton, Heather A., additional, Hurt, Ryan, additional, Kasten, Mary J., additional, Lee, Augustine S., additional, Levy, Emily R., additional, Libertin, Claudia R., additional, Mallea, Jorge M., additional, Marshall, William F., additional, Matcha, Gautam, additional, Meehan, Anne M., additional, Franco, Pablo Moreno, additional, Morice, William G., additional, O’Brien, Jennifer J., additional, Oeckler, Richard, additional, Ommen, Steve, additional, Oravec, Caitlin P., additional, Orenstein, Robert, additional, Ough, Natalie J., additional, Palraj, Raj, additional, Patel, Bhavesh M., additional, Pureza, Vincent S., additional, Pickering, Brian, additional, Phelan, David M., additional, Razonable, Raymund R., additional, Rizza, Stacey, additional, Sampathkumar, Priya, additional, Sanghavi, Devang K., additional, Sen, Ayan, additional, Siegel, Jason L., additional, Singbartl, Kai, additional, Shah, Aditya S., additional, Shweta, FNU, additional, Speicher, Leigh L., additional, Suh, Gina, additional, Tabaja, Hussam, additional, Tande, Aaron, additional, Ting, Henry H., additional, Tontz, Russell C., additional, Vaillant, James J., additional, Vergidis, Paschalis, additional, Warsame, Mohamed Y., additional, Yetmar, Zachary A., additional, Zomok, Catherine (Cate) D., additional, Williams, Amy W., additional, and Badley, Andrew D., additional

Published
2021
Full Text
View/download PDF

6. Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis

Author

Karau, Melissa J, primary, Schmidt-Malan, Suzannah M, additional, Albano, Mariana, additional, Mandrekar, Jayawant N, additional, Rivera, Christina G, additional, Osmon, Douglas R, additional, Oravec, Caitlin P, additional, Berry, Daniel J, additional, Abdel, Matthew P, additional, and Patel, Robin, additional

Published
2020
Full Text
View/download PDF

8. 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection

Author

Albano, Mariana, Karau, Melissa J, Osmon, Douglas R, Oravec, Caitlin P, Abdel, Matthew P, and Patel, Robin

Subjects
Abstracts, Poster Abstracts, polycyclic compounds, biochemical phenomena, metabolism, and nutrition
Abstract

Background Prosthetic joint infections (PJIs) are serious complications after total joint arthroplasty. Staphylococcus aureus and Staphylococcus epidermidis, which are proficient biofilm-formers, account for ~60% of PJI cases. Therapy often includes rifampin because of its anti-biofilm activity; the activity of other rifamycins against staphylococcal biofilms is poorly defined. This study evaluated the in vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against S. aureus and S. epidermidis biofilms formed by isolates from patients with PJI. Methods 200 staphylococcal isolates were tested (111 S. aureus and 89 S. epidermidis). All S. aureus isolates, and all except 7 S. epidermidis isolates, were rifampin susceptible. Rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm bactericidal concentration (MBBCs) were determined using a pegged lid microtiter plate assay. Results Rifampin-resistant isolates had MBICs and MBBCs ≥16 µg/mL. Results for the rifampin-susceptible isolates are shown. All 193 rifampin-susceptible isolates had rifampin MBICs ≤1 µg/mL (rifampin-susceptible breakpoint for planktonic susceptibility testing), with 1, 2, and 2 isolates having MBICs > 1 µg/mL for rifabutin, rifapentine and rifaximin, respectively. S. aureus MBBC50 values were 8, 1, 2 and 4 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively. S. epidermidis MBBC50 values were 2, 0.06, 0.25, and 0.5 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively, for rifampin-susceptible isolates. Conclusion Rifabutin and rifapentine, and to a lesser extent, rifaximin, show promising in vitro activity against rifampin-susceptible staphylococcal biofilms formed by isolates associated with PJI; studies evaluating in vivo activity are warranted. Disclosures All authors: No reported disclosures.

Published
2019

9. In VitroActivity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection

Author

Albano, Mariana, Karau, Melissa J., Greenwood-Quaintance, Kerryl E., Osmon, Douglas R., Oravec, Caitlin P., Berry, Daniel J., Abdel, Matthew P., and Patel, Robin

Abstract

The in vitroactivities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high.

Published
2019
Full Text
View/download PDF

10. Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research.

Author

O'Horo JC, Cerhan JR, Cahn EJ, Bauer PR, Temesgen Z, Ebbert J, Abril A, Abu Saleh OM, Assi M, Berbari EF, Bierle DM, Bosch W, Burger CD, Cano Cevallos EJ, Clements CM, Carmona Porquera EM, Castillo Almeida NE, Challener DW, Chesdachai S, Comba IY, Corsini Campioli CG, Crane SJ, Dababneh AS, Enzler MJ, Fadel HJ, Ganesh R, De Moraes AG, Go JR, Gordon JE, Gurram PR, Guru PK, Halverson EL, Harrison MF, Heaton HA, Hurt R, Kasten MJ, Lee AS, Levy ER, Libertin CR, Mallea JM, Marshall WF 3rd, Matcha G, Meehan AM, Franco PM, Morice WG 2nd, O'Brien JJ, Oeckler R, Ommen S, Oravec CP, Orenstein R, Ough NJ, Palraj R, Patel BM, Pureza VS, Pickering B, Phelan DM, Razonable RR, Rizza S, Sampathkumar P, Sanghavi DK, Sen A, Siegel JL, Singbartl K, Shah AS, Shweta F, Speicher LL, Suh G, Tabaja H Jr, Tande A, Ting HH, Tontz RC 3rd, Vaillant JJ, Vergidis P, Warsame MY, Yetmar ZA, Zomok CCD, Williams AW, and Badley AD

Subjects
Adolescent, COVID-19 epidemiology, Child, Child, Preschool, Female, Follow-Up Studies, Hospitalization trends, Humans, Infant, Infant, Newborn, Intensive Care Units statistics & numerical data, Male, Retrospective Studies, Biomedical Research, COVID-19 therapy, Pandemics, SARS-CoV-2
Abstract

Objective: To report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19) related to patient outcomes., Methods: We conducted a retrospective chart review of patients with COVID-19 diagnosed between March 1, 2020, and July 31, 2020, at any of the Mayo Clinic sites. We abstracted pertinent comorbid conditions such as age, sex, body mass index, Charlson Comorbidity Index variables, and treatments received. Factors associated with hospitalization and mortality were assessed in univariate and multivariate models., Results: A total of 7891 patients with confirmed COVID-19 infection with research authorization on file received care across the Mayo Clinic sites during the study period. Of these, 7217 patients were adults 18 years or older who were analyzed further. A total of 897 (11.4%) patients required hospitalization, and 354 (4.9%) received care in the intensive care unit (ICU). All hospitalized patients were reviewed by a COVID-19 Treatment Review Panel, and 77.5% (695 of 897) of inpatients received a COVID-19-directed therapy. Overall mortality was 1.2% (94 of 7891), with 7.1% (64 of 897) mortality in hospitalized patients and 11.3% (40 of 354) in patients requiring ICU care., Conclusion: Mayo Clinic outcomes of patients with COVID-19 infection in the ICU, hospital, and community compare favorably with those reported nationally. This likely reflects the impact of interprofessional multidisciplinary team evaluation, effective leveraging of clinical trials and available treatments, deployment of remote monitoring tools, and maintenance of adequate operating capacity to not require surge adjustments. These best practices can help guide other health care systems with the continuing response to the COVID-19 pandemic., (Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results